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Title: Clinical leishmaniasis in dogs living in the UK          1 
Abstract:  2 
 3 
Objective: To investigate the prevalence of leishmaniasis in a canine population in the UK and to describe 4 
clinical presentation, clinicopathological abnormalities, therapeutic protocols and outcome in this non-5 
endemic country.  6 
 7 
Materials and Methods: Medical records of dogs diagnosed with leishmaniasis at 7 referral centres in the 8 
UK were retrospectively reviewed.  9 
 10 
Results: The prevalence was between 0.007 and 0.04% with a higher number of cases in southern England. 11 
All dogs had a history of travel to or from an endemic country. Lethargy, dermatological signs, decreased 12 
appetite and lameness were the most common reasons for presentation. Allopurinol was used alone in the 13 
majority of cases.  14 
 15 
Clinical significance: Although rare, CanL in the UK should be considered in patients showing compatible 16 
clinical signs and with a history of travel to or from endemic areas.  17 
 18 
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INTRODUCTION 29 
Canine leishmaniasis (CanL) is a systemic zoonotic disease caused by the protozoan Leishmania infantum. 30 
Infected dogs are the main reservoir of the parasite (Baneth et al. 2008) and play an important role in the 31 
epidemiology of human visceral (HVL) and cutaneous (HCL) leishmaniasis. Approximately 0.2 to 0.4 and 0.7 32 
to 1.2 million HVL and HCL cases, respectively, occur each year. More than 90% of global HVL cases occur 33 
in six countries: India, Bangladesh, Sudan, South Sudan, Ethiopia and Brazil. HCL is more widely distributed 34 
with about one-third of cases occurring in each of three epidemiological regions, the Americas, the 35 
Mediterranean basin, and western Asia from the Middle East to Central Asia (Alavar et al. 2012). CanL is 36 
endemic in more than 70 countries worldwide (Solano-Gallego et al. 2011) and especially in the 37 
Mediterranean areas of Europe (Cyprus, Greece, Albania, Croatia, Italy, Malta, France, Spain and Portugal) 38 
(Maia & Cardoso 2015), the Middle East and many tropical and subtropical areas of the world. However, the 39 
infection is spreading to non-endemic areas with an increasing number of cases reported in dogs living in 40 
North America (Gaskin et al. 2002, Duprey et al. 2006) and Northern Europe (Shaw et al. 2009, Maia & 41 
Cardoso 2015). Recent studies have documented the presence of the disease in Germany (Geisweid et al. 42 
2012), United Kingdom (Shaw et al. 2009) and Netherlands (Teske et al. 2002). This is probably due to a 43 
wider spread of the vector in some of the above areas and especially to a larger numbers of dogs being 44 
imported from, or having visited, endemic countries. Since the introduction of the United Kingdom Pet Travel 45 
Scheme (PETS) in 2000, the number of dogs travelling into the UK has increased year after year with a total 46 
of 411,582 dogs recorded between 2000 and January 2008 (Mencke et al. 2011). As a result, the disease has 47 
gained importance in the UK, albeit largely limited to the dogs that travel. It is likely that only very little 48 
natural transmission occurs in the UK because environmental conditions prevent the viability of the vector 49 
(Shaw et al. 2009). However, other mechanisms of transmission are possible, including blood transfusion (de 50 
Freitas et al. 2006), vertical (Rosypal et al. 2005, Pangrazio et al. 2009, Boggiatto et al. 2011, Naucke et al. 51 
2012, Turchetti et al. 2014) and venereal transmission (Diniz et al. 2006).   Despite the increase in awareness, 52 
the prevalence of infected dogs entering the UK is unknown, as no pre-or post-travel testing is required. 53 
Furthermore, clinically apparent cases represent the minority of infected dogs in endemic areas (Solano-54 
Gallego et al. 2009; Schallig et al. 2013), so dogs with subclinical infection that appear healthy may 55 
unknowingly be imported. 56 
Only one study (Shaw et al. 2009) has previously investigated dogs with positive diagnostic tests for CanL in 57 
the UK. The objectives of this study were, firstly, to investigate the prevalence of leishmaniasis in a canine 58 
population attending referral centres in the UK and, secondly, to describe clinical presentation, most frequent 59 
clinicopathological abnormalities, diagnostic investigations, different therapeutic protocols used and outcome 60 
of dogs diagnosed with CanL in this non-endemic country.  61 
 62 
MATERIALS AND METHODS 63 
Patients and eligibility 64 
Medical records of dogs diagnosed of clinical leishmaniasis in seven different referral centres in the UK 65 
(University of Liverpool, University of Bristol, University of Edinburgh, University of Cambridge, Royal 66 
Veterinary College of London, Anderson Moores Veterinary Specialists, Animal Health Trust), between 67 
January 2005 and January 2014, were retrospectively reviewed. The database of each institution was searched 68 
by use of the following terms: leishmaniasis, leishmaniosis, allopurinol, N-methylglucamine antimoniate and 69 
miltefosine. Dogs on therapy with allopurinol for other diseases than CanL were excluded. In this way only 70 
patients with a final diagnosis of clinical leishmaniasis were selected and then included.  The prevalence of 71 
the disease was calculated as the percentage of the ratio between the number of cases diagnosed of CanL in 72 
the study period at each referral centre and the total canine population that attended the respective centre in 73 
the same time period. The study was approved by the Veterinary Research Ethics Committee of the University 74 
of Liverpool. 75 
 76 
Data collection 77 
The diagnosis of CanL was made when there were compatible clinical signs and/or laboratory abnormalities 78 
together with detection of the parasites by polymerase chain reaction (PCR) or cytology (from lymph node, 79 
bone marrow, spleen or skin), and/or detection of antibodies using an immunofluorescence assay (IFAT) or an 80 
enzyme-linked immunosorbent assay (ELISA). Where available, information was reviewed regarding travel 81 
history (i.e. country to which the dog had travelled or from where it had been imported), reasons for 82 
presentation, physical examination findings, results of diagnostic investigations (e.g. haematology, 83 
biochemistry, urinalysis, cytology, serology, and PCR), therapeutic protocol used, and outcome. Dogs were 84 
tested for other vector-borne diseases (Ehrlichia canis, Babesia canis) if a co-infection was suspected. 85 
Survival time was defined as time (in days) from first presentation to last re-check or to time of death. 86 
 87 
Diagnostic investigations 88 
All routine clinicopathological analyses, serology, and real-time quantitative PCR (qPCR) assays were 89 
conducted at the respective university or by commercial laboratories.  Clinicopathological abnormalities such 90 
as anaemia, azotaemia, hypoalbuminaemia were defined when results were outside the reference intervals 91 
established by each corresponding laboratory. Proteinuria was diagnosed by an elevated urine protein-to-92 
creatinine ratio (UPCR >0.5) with inactive urinary sediment. Renal azotaemia was defined as increased 93 
creatinine with concurrent isosthenuria (1.008-1.012).  94 
For serological investigations, the upper reference interval for IFAT was either 1:80 or 1:128, depending on 95 
the laboratory, whilst the positive threshold value for ELISA used by all laboratories was 35 ELISA Units 96 
(EU). Serological results were classified as low, medium or high positive if IFAT titres were  <2-fold, 2- to 4-97 
fold, or >4-fold greater than the threshold positive value indicated by the reference laboratory. ELISA results 98 
were classified as mild when <80 EU, moderate when between 80 and 150 EU, and high when >150 EU. 99 
Detection and quantification of Leishmania kinetoplastic DNA was performed on blood, bone marrow, and/or 100 
skin samples by qPCR as previously described (Caldin et al. 2004, Solano-Gallego et al. 2007, Maia et al. 101 
2008).  102 
 103 
Classification of cases 104 
Dogs were classified at the time of diagnosis in different clinical stages according to the Canine Leishmaniasis 105 
Working Group (CLWG) guidelines (Paltrinieri et al. 2010). Dogs were also classified according to the 106 
International Renal Interest Society (IRIS) guidelines, based on measurement of serum creatinine 107 
concentration at the first two appointments. 108 
 109 
Statistical analysis:  110 
Data are reported as median or mean and range (minimum and maximum). 111 
 112 
RESULTS: 113 
Patient population 114 
Thirty-eight dogs were included in the study: 14 were diagnosed at the Royal Veterinary College, 7 at the 115 
University of Liverpool, 7 at the University of Edinburgh, 3 at the University of Bristol, 3 at the University of 116 
Cambridge, 3 at the Animal Health Trust and 1 at Anderson Moores Veterinary Specialists. Median age was 117 
4.8 years (range 1.11 years-12.2 years) and median body weight was 26.3 kg (range 5.9-49 kg). The 118 
prevalence of the disease was between 0.007 and 0.04 per cent and higher incidences (0.04 per cent at the 119 
Royal Veterinary College of London, 0.03 per cent at the University of Bristol and 0.02 per cent at the Animal 120 
Health Trust) were found in southern England. 121 
All dogs had a history of having travelled to or been imported from an endemic area for Leishmania infantum. 122 
No clinical or clinicopathological differences were noted between dogs imported from and dogs that have 123 
travelled to an endemic area. No autochthonous cases were found in this population. Details of patient and 124 
travel history are presented in Table 1. 125 
 126 
Detection of Leishmania infantum and concurrent vector-borne diseases 127 
Leishmania infantum infection was demonstrated by serology and/or PCR and/or cytology. Details of the 128 
diagnostic tests are shown in Table 2. Only three dogs were tested for other vector-borne diseases, including 129 
two dogs tested by serology for Ehrlichia canis and one for Babesia canis.  All three dogs were negative.  130 
 131 
Clinical signs 132 
All dogs had at least one clinical sign compatible with leishmaniasis. The most frequent reasons for 133 
presentation were lethargy (20/38, 53%), dermatological manifestations (17/38, 45%), decreased appetite and 134 
lameness (8/38, 21%). On physical examination the most common signs observed were dermatological signs 135 
(24/38, 63%, including localised or multifocal alopecia [10], and crusting dermatitis [8]) and systemic 136 
lymphadenopathy (22/38, 58%). Twenty-four per cent (9/38) of dogs were diagnosed with polyarthritis. 137 
 138 
Clinicopathological investigations 139 
Table 3 shows the main clinicopathological findings. All dogs had at least one laboratory abnormality 140 
compatible with leishmaniasis. In total, 19/32 dogs (60%) were anaemic, with the anaemia being classified as 141 
mild (haematocrit [HCT] 30-36%) and moderate (HCT 18-29%) in 11 (58%) and 8 dogs (42%), respectively, 142 
and also classified as non-regenerative (reticulocytes < 60 x 109/L) in 4 of the 6 cases where reticulocyte 143 
count was available. Eight dogs (8/23, 35%) had thrombocytopenia (median: 94 x 109/L, range: 30-150; 144 
laboratory reference interval: 155-400)  and two (2/22, 9%) were pancytopenic. Renal azotaemia was detected 145 
in 6 dogs (6/25, 24%) and 20 dogs (20/30, 67%) were classified as being in IRIS stage 1 CKD (creatinine < 146 
125 µmol/l), 4 (4/30, 13%) in IRIS stage 2 (creatinine between 125-180 µmol/l) and 6 (6/30, 20%) in IRIS 147 
stage 3 (creatinine between 181-440 µmol/l). None of the dogs were classified as being in IRIS stage 4 CKD 148 
(creatinine > 440 µmol/l). Nineteen (19/28, 78%) of dogs were proteinuric based on increased UPCR (median: 149 
5.6, range: 0.7-18.8; normal values < 0.5). Finally, 28 dogs (28/30, 93%) had hypoalbuminaemia (median: 16 150 
g/l, range: 11-20, laboratory reference interval: 23-31), hyperglobulinaemia (median: 58 g/l, range: 52.1-70; 151 
laboratory reference interval: 25-45) and a low (<0.6) albumin/globulin ratio. Serum protein electrophoresis 152 
was rarely used in the diagnostic work-up and/or in the follow-up rechecks.  153 
 154 
Treatment 155 
Of the 38 cases, 35 (92%) were given a specific treatment for CanL. In the majority of cases (17/35, 48%) 156 
allopurinol was used alone, followed by a combination of allopurinol and miltefosine (15/35, 43%) or 157 
allopurinol and N-methylglucamine antimoniate (3/35, 9%). A variety of other drugs were used in addition to 158 
the anti-Leishmania therapy, depending upon the specific case and attending clinician’s judgement.  159 
Treatments included ace-inhibitors (benazepril, enalapril) anti-hypertensive drugs (amlodipine), anti-160 
thrombotics (clopidogrel, aspirin) analgesics and anti-inflammatory drugs (tramadol, meloxicam), gastro-161 
protectants (sucralfate, famotidine), anti-emetics (maropitant, ondansetron, metoclopramide), immune-162 
suppressive drugs (prednisolone, azathioprine), diuretics (spironolactone), antibiotics (doxycycline, 163 
amoxicillin-clavulanate, enrofloxacin and marbofloxacin). 164 
 165 
Staging and survival 166 
Based on CLWG clinical staging, 32 dogs (32/38, 84%) were classified as stage C (sick dogs with clinically 167 
evident leishmaniasis), and 6 (6/38, 16%) as stage D (severely sick dogs often unresponsive to repeated 168 
courses of anti-Leishmania drugs). Twenty-eight (28/38, 74%) dogs were alive at the end of the study period 169 
and ten (10/38, 26%) had died or had been euthanased. Six of the ten non-surviving dogs (60%) were 170 
classified in stage D and 4 (4/10, 40%) in stage C. Median survival time was 400 days (range 2-2160 days). 171 
Reasons for death and/or euthanasia included worsening of kidney disease (3/10, 30%), lack of response to 172 
therapy (3/10, 30%), acute thrombo-embolism (1/10, 10%), neurological signs due to myelomalacia likely 173 
secondary to severe systemic vasculitis (1/10, 10%) and developing of lymphoma (1/10, 10%) and 174 
osteosarcoma (1/10, 10%). 175 
 176 
DISCUSSION: 177 
In this study data from dogs diagnosed with leishmaniasis in seven different referral centres across the UK are 178 
reported. This is the first time that clinical CanL has been described in all its aspects in a population living in 179 
the UK. The prevalence of the disease in this study was low demonstrating that leishmaniasis is relatively 180 
uncommon in dogs living in the UK.  However, the real prevalence of the disease is likely higher than the 181 
current report suggests since no cases from primary practices were included. Furthermore, only dogs with 182 
clinical leishmaniasis were considered, with either exposed or infected animals (those having positive results 183 
to the diagnostic tests but not showing any clinical and clinicopathological abnormalities of the disease) not 184 
being considered. It is unpredictable whether those dogs will develop clinical signs in the future. Moreover, 185 
due to the low familiarity of the veterinary surgeons in the UK with this disease, it is possible that some cases 186 
have been missed because CanL was not considered among the possible differentials. In addition, some clients 187 
could have declined serology testing. 188 
Unfortunately, in many cases the time-frame between the travel from/to endemic areas and the development 189 
of clinical signs was not available. Anyway, it is well known that the time between the infection and the 190 
development of the clinical signs (incubation period) can be very variable and mainly dependent to the host’s 191 
immunologic response (Fisa et al. 1999, Cardoso et al. 2007). 192 
Similar to previous reports (Shaw et al. 2009), most cases were found in southern England.  However, caution 193 
should be exercised when interpreting this because no all geographical regions across the UK were included in 194 
the present study. If cases from the south are genuinely overrepresented, it might be due to easier connections 195 
to Europe and warmer weather.  With regard to the latter, the climate has recently changed enough to support 196 
the transmission and diffusion in these areas of other vector borne diseases (Medlock et al. 2007; Wilson et al. 197 
2013). However, to date a vector of L. infantum has not been found in the UK and sand flies that are 198 
introduced in the country by car or plane likely die soon after arrival due to a marked intolerance to climate 199 
changes. In fact, the sand fly’s range of activity is between 15° and 28°C in association with high relative 200 
humidity and absence of strong rain and winds (Bogdan et al. 2001, Killick-Kendrick, 1999, Maroli et al. 201 
2013). This does not rule out possible future epidemiological changes due to the ongoing global warming. To 202 
date, there is little published information regarding the distribution of the competent sand fly in Northern 203 
Europe and in the UK and how or if it is changing due to the warmer climate. Furthermore, other modes of 204 
transmission have been described including blood transfusion (de Freitas et al. 2006), vertical transmission 205 
from bitches to puppies (Rosypal et al. 2005, Pangrazio et al. 2009, Boggiatto et al. 2011, Naucke et al. 2012, 206 
Turchetti et al. 2014) and venereal transmission (Diniz et al. 2006). Dog-to-dog mechanisms have been also 207 
hypothesised to explain leishmaniasis outbreaks among foxhounds in the United States and Canada (Duprey et 208 
al. 2006).  209 
 210 
All dogs included in the present study had a history of having travelled to or been imported from a region 211 
endemic for Leishmania infantum. The majority of dogs were imported (32/38, 84%) versus a minority that 212 
has travelled to an endemic country (6/38, 16%). This would suggest a higher risk in adopting a dog from an 213 
endemic area respect travelling with the dog to those countries. Travelling dogs usually stay for only a short 214 
period time and the overall risk they get infected with L. infantum is likely low (Hamel et al. 2011). However, 215 
veterinarians in non-endemic regions should be aware of CanL, including its non-vectorial transmission 216 
modes, and should advise dog owners on preventive measures (Shaw et al. 2009, Menn et al. 2010). The 217 
majority of dogs in the present study had been in Spain, which is compatible with the high prevalence of 218 
leishmaniasis in this country (Mattin et al. 2014) and its popularity as a destination for holidays.  Imported 219 
shelter and stray dogs have higher risk to be infected because of decreased preventive measures  and greater 220 
exposure to sand flies during the period of peak of activity (evening) (Manzillo et al. 2006). No 221 
autochthonous cases were recognised in this study, which contrasts the findings of Shaw et al. (2009) who 222 
identified 3 positive dogs obtained from UK re-homing centres with no history of travel abroad. It remains 223 
questionable if transmission was due to vectors, transplacental or even by direct contact. 224 
 225 
The spectrum of clinical signs and laboratory abnormalities in the study group of dogs were similar to that 226 
reported in endemic areas (Ciaramella et al. 1997, Koutinas et al. 1999, Paltrinieri et al. 2010, Solano-Gallego 227 
et al. 2011). Dermatological signs and lymphadenopathy were the most frequent clinical findings.  228 
Polyarthritis was present in 9 dogs (24%), similarly to previously published work from the UK (Shaw et al. 229 
2009) (17%). Polyarthritis should be then considered among common presenting signs of leishmaniasis in 230 
dogs diagnosed in UK referral centres. The most frequent clinico-pathological abnormalities found in the 231 
study group included mild-to-moderate anaemia, renal azotaemia, hyperglobulinaemia, hypoalbuminaemia, 232 
decreased albumin/globulin ratio and proteinuria. These are considered hallmarks of CanL also in endemic 233 
areas (Ciaramella et al. 1997, Koutinas et al. 1999, Paltrinieri et al. 2010, Solano-Gallego et al. 2011). 234 
Given that non-pathognomonic clinical signs and laboratory abnormalities, as well as the low familiarity with 235 
the disease of the veterinary surgeons in the UK, more than one test was used to confirm the final diagnosis in 236 
the majority of cases. Serology and PCR on peripheral blood was the most common combination of diagnostic 237 
tests used in this population. However, PCR on peripheral blood lacks sensitivity and different tissues such as 238 
lymph nodes, spleen and/or bone marrow would harbour a higher number of Leishmania amastigotes (Caldin 239 
et al. 2004). Furthermore, serum protein electrophoresis was included in the initial diagnostic investigation 240 
and in follow-up rechecks only in a very low number of cases. However, this test can provide important 241 
information, especially during reassessment, because improvement or normalisation of the protein 242 
electrophoresis trace generally happens before a negative serology titre occurs (Torres et al. 2011). At time of 243 
diagnosis, the authors recommend the evaluation of haematology, biochemistry profile, urinalysis including 244 
UPCR, serology titre and serum protein electrophoresis. In case of peripheral lymphadenopathy and/or skin 245 
lesions, fine-needle aspiration for cytology and/or PCR can be also useful. After the first month of therapy, 246 
previous abnormal parameters can be re-checked together with serum protein electrophoresis: in fact, as stated 247 
before, this test will the first one to show an improvement or even a normalisation of previous 248 
hypoalbuminaemia and hyperglobulinaemia (usually polyclonal gammopathy). At this stage, a significant 249 
reduction of the serology titre is unlikely. The latter is generally re-evaluated at 3 and 6 months from 250 
diagnosis together with quantitative PCR on lymph-nodes, spleen and/or bone marrow that can demonstrate a 251 
progressive reduction of the number of amastigotes.  252 
 253 
The majority of dogs were treated with allopurinol alone, most likely because N-methylglucamine antimoniate 254 
is not available in the UK and must be imported and miltefosine requires a special treatment certificate. Where 255 
additional anti-Leishmania drugs were used, miltefosine was more frequently used than N-methylglucamine 256 
antimoniate, probably because it is an oral solution and easier to administer. In contrast, N-methylglucamine 257 
antimoniate must be injected subcutaneously, and can often be associated with localised pain and 258 
inflammation.  Anyway, both drugs have been previously shown to be similarly effective (Miró et al. 2009). 259 
Currently, N-methylglucamine antimoniate or miltefosine in association with allopurinol are recommended as 260 
standard therapy for CanL (Oliva et al 2010, Solano-Gallego et al. 2011, Roura et al 2013, Noli et al. 2014). 261 
Some dogs also received other drugs according to the attending clinician’s decision. The influence of these 262 
drugs on the anti-Leishmania therapy and outcome is unknown. 263 
 264 
Considering that the majority of dogs were treated only with allopurinol, it is noteworthy that the overall 265 
outcome was good with a reasonable survival time. Furthermore, it should be considered that only dogs with 266 
moderate-to-severe disease (stages C and D) were included in the study and that these animals generally have 267 
a guarded-to-poor prognosis in endemic areas (Solano-Gallego et al. 2011; Roura et al. 2013). This finding 268 
can, perhaps, be explained by the minimal chance of re-infection given the geographical location, and low risk 269 
of having a concurrent vector-borne disease (Shaw et al. 2009). The latter cannot be completely ruled out in 270 
this study population since only three dogs were tested for other vector-borne diseases. In this respect, 271 
response to CanL is known to be influenced by both concurrent disease and immunological stimulation or 272 
suppression by shifting the balance from a protective Th1 response to a Th2 immune response that favours the 273 
development of a non-protective and possibly detrimental humoral reaction (Koutinas et al. 2014). 274 
Most non-surviving dogs experienced a worsening of kidney disease. It is recognised that advanced renal 275 
failure is the major cause of death and/or euthanasia in CanL (Panellas et al. 2009).  Further studies evaluating 276 
IRIS staging in a bigger population and also in patients already on therapy could provide more useful 277 
information regarding its possible prognostic value.   278 
Finally, all dogs in clinical stage D died or were euthanased. Currently clinical staging at time of diagnosis 279 
and periodic re-classification in line with disease progression and regression is considered a useful way to 280 
predict outcome (Solano-Gallego et al. 2009, Oliva et al. 2010, Paltrinieri et al. 2010). 281 
 282 
In conclusion, although rare, veterinary surgeons in the UK should consider CanL in patients with a history of 283 
travel to or from endemic areas, where there are compatible clinical signs and clinicopathological 284 
abnormalities. An early diagnosis and appropriate therapy can be associated with a relatively good control of 285 
the disease (Roura et al. 2013; Torres et al. 2011). As Leishmania infection is known to have a long 286 
incubation period, practitioners should inform the owners of imported dogs to retest them for Leishmania for 287 
at least two years after importation or in case of a clinical suspicion (Paltrinieri et al. 2010). Moreover, 288 
veterinarians should be aware of non-vectorial transmission ways, and should advice clients on preventive 289 
measures before travelling to endemic countries.  290 
 291 
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Table 1: Patient population & travel history 
 Number of 
dogs (%) 
Mixed breed 
Labrador retriever 
Lurcher 
Cocker spaniel 
Golden retriever 
Staff bull terrier 
Basset hound 
Border collie 
Boxer 
English pointer 
English setter 
Greek hare hound 
Greyhound 
Siberian husky 
Labradoodle 
Miniature poodle 
Miniature schnauzer 
Rottweiler 
Spanish galgo 
 
Neutered males 
Neutered females 
Entire males 
Entire female 
12 (31%) 
   4 (10%) 
 3 (8%) 
 2 (5%) 
 2 (5%) 
 2 (5%) 
 1 (3%) 
  1 (3%)   
  1 (3%) 
 1 (3%) 
 1 (3%) 
 1 (3%) 
 1 (3%) 
 1 (3%) 
 1 (3%) 
 1 (3%) 
 1 (3%) 
 1 (3%) 
 1 (3%) 
 
18 (47%)  
  15 (40%) 
 3 (8%) 
 2 (5%)   
Imported from 32 (84%) 
Spain 
Greece 
Cyprus 
Italy 
Portugal 
Hungary 
Brazil 
16 (42%) 
  7 (18%) 
  3 (8%) 
  2 (5%) 
  2 (5%) 
  1 (3%) 
  1 (3%) 
Traveled to    6 (16%) 
Spain 
France 
Germany    3 (8%)    2 (5%)    1 (3%) 
                    
Table 2: Diagnostic tests used to indentify L. infantum infection 
 Number of 
dogs (%) 
Serology + PCR 
Serology + PCR + Cytology 
Serology 
PCR 
Serology + Cytology 
PCR + Cytology 
Cytology 
10 (26%) 
8 (21%) 
7 (18%) 
7 (18%) 
3 (8%) 
2 (5%) 
1 (2%) 
Serology 28 (74%) 
ELISA 
IFAT 
 
Mild 
Moderate 
High 
19 (68%) 
9 (32%) 
 
7 (25%) 
11 (39%) 
10 (36%) 
PCR 27 (71%) 
Blood 
Spleen 
Lymph node 
Bone marrow 
Blood + Bone marrow 
Blood + Spleen 
Spleen + Lymph node 
Blood + Conjunctiva + Skin 
Blood + Bone marrow + Joint fluid 
12 (44%) 
4 (15%) 
3 (11%) 
2 (7%) 
2 (7%) 
1 (4%) 
1 (4%) 
1 (4%) 
1 (4%) 
Cytology 14 (37%) 
Lymph node 
Spleen 
Bone marrow 
Lymph node + Spleen 
 
8 (57%) 
3 (22%) 
2 (14%) 
1 (7%) 
 
 
